Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-303 in Female Patients With Stress Urinary Incontinence
NCT02562807Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAS-303 in stress urinary incontinence (SUI) (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in Maximum Urethral Closure Pressure. Started Oct 2015; status: completed.
02
Drugs
TAS-303
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT02562807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562807.